Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Immuron Limited

35 indications, side-by-side phase, drug & LoA

$1.19

-0.05 (-4.03%)

C 45Pipeline Score Fair Value Pharma · Clinical
Market Cap
7.45 M
EPS
-0.48
P/E Ratio
-
Value Trade
138.01 K
-4.76 %
Week
8.21 %
1 Month
36.99 %
3 Month
-37.5 %
6 Month
-80.12 %
5 Year
-89.19 %
All Time
Cash Data

  • Cash Position

    12.35 K

  • Monthly Burn

    12.35 K

  • Runway

    12,345 mo

Overview
Volume
24.79 K
52 Week Range
0.68 - 2.39
% held by Insiders
-
% held by Institutions
1.04 %
Enterprise Value
781.27 K
Total Shares
8.17 M
Short %
16.39 %
Float Shares
-
Company Description
Employees:7
https://www.immuron.com.au

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Phase 2 data readout example
IMM-529 Recurrent Clostridioides difficile infection (CDI)
Phase 2
—
-
-
IMM-529 Recurrent Clostridioides difficile infection (CDI)
Phase 2
—
-
-
IMM-529 Recurrent Clostridioides difficile infection (CDI)
Phase 2
—
-
-
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
C45
Pipeline Score
$11M
Pipeline Value
Fair Value
Valuation Signal
2
Drugs Scored
1.5x
rNPV / MCap
Top 68%
Micro Cap
(rank 291 of 905)
Percentile Rank
Immuron Limited carries a moderate pipeline score (45/100), with $4.5B risk-adjusted pipeline value, led by IMM-124E in Nonalcoholic Fatty Liver Disease (NAFLD) (Phase 2), across $71B in total addressable markets.
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
IMM-124E
Monoclonal antibody		Nonalcoholic Fatty Liver Disease (NAFLD)Phase 2NCT0304276760% $2.4B COMPLETED 40 - -Oct 23, 2019 -May 24, 2021
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
IMM-529
Clostridioides difficile infection (CDI),prevention of recurrent CDI (rCDI)
Phase 2
2025-10-08
IMM-529
Clostridioides difficile infection (CDI),prevention of recurrent CDI (rCDI)
Phase 2
2025-10-08
IMM-529
Clostridioides difficile infection (CDI),prevention of recurrent CDI (rCDI)
Phase 2
2025-10-08
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in IMRN
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
IMRN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
IMRN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
IMRN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
IMRN Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
IMRN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Immuron Limited (IMRN) News & Alerts
-
Sunday, June 14, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How IMRN ranks across every disease it competes in
No competitive intelligence available for IMRN.